A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics After High Single Ascending Oral Doses of AZD1656 in T2DM Patients

Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Male, T2DM patients aged 20-60 years * Treatment with 1 to 2 OADs as Therapy for T2DM for at least 30 days prior to enrollment * Patients should not have been treated with glitazones within 6 months prior to enrollment * Male T2DM patients without known cardiovascular disease, with the exception of Grade 1 hypertension without secondary organ involvement (eg. grade 1 HT is allowed if no eye, kidney disease or LVH has been documented). Exclusion Criteria: * History of ischemic heart disease , heart failure, stroke, transitory ischemic attack or peripheral vascular disease. * Prolonged QTcF\>450 msec or shortened QTcF\<350 msec or family history of long QT syndrome. * Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. * Systolic BP\>159 mmHg or diastolic BP\>99 mmHg at screening and on Day-1